Get the Stockscreener App
43.46
0.80%
-0.35
Praxis Precision Medicines Inc stock is traded at $43.46, with a volume of 210.65K.
It is down -0.80% in the last 24 hours and up +17.40% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
See More
Previous Close:
$43.81
Open:
$43.35
24h Volume:
210.65K
Relative Volume:
0.53
Market Cap:
$933.92M
Revenue:
$1.77M
Net Income/Loss:
$-123.74M
P/E Ratio:
-4.7394
EPS:
-9.17
Net Cash Flow:
$-95.21M
1W Performance:
-5.21%
1M Performance:
+17.40%
6M Performance:
-40.47%
1Y Performance:
+18.91%
1-Day Range:
$41.64
$44.26
1-Week Range:
$41.64
$46.93
52-Week Range:
$26.70
$91.83
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
43.46 | 933.92M | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-03-25 | Reiterated | H.C. Wainwright | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
Praxis Precision Medicines (NASDAQ:PRAX) Given Buy Rating at Needham & Company LLC - Defense World
Needham Reiterates Buy Rating on Praxis Precision Medicine (PRAX) with $80 Price Target | PRAX Stock News - GuruFocus
Bank of America Corp DE Reduces Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
California State Teachers Retirement System Acquires 275 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 2,747 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Ameriprise Financial Inc. Buys Shares of 3,227 Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Day 8 of Gains Streak for Praxis Precision Medicines Stock with 23% Return (vs. -42% YTD) [6/6/2025] - Trefis
Weston investment banker pleads guilty to insider trading offense - Westfair Communications
Trading (PRAX) With Integrated Risk Controls - news.stocktradersdaily.com
Praxis Precision Medicines, Inc. Announces Inducement Grants Und - GuruFocus
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Praxis Precision Medicines Strengthens Talent Acquisition with New RSU Grant Program - Stock Titan
Can PRAX Rebound On Multiple Upcoming Epilepsy Trial Readouts? - RTTNews
Two Sigma Investments LP Lowers Stock Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Given a $97.00 Price Target at Oppenheimer - Defense World
Oppenheimer assigns outperform rating to Praxis Precision Medicines stock By Investing.com - Investing.com Canada
Oppenheimer Sets Price Target of $97 on PRAX with Outperform Rat - GuruFocus
Oppenheimer Sets Price Target of $97 on PRAX with Outperform Rating | PRAX Stock News - GuruFocus
Oppenheimer assigns outperform rating to Praxis Precision Medicines stock - Investing.com
Praxis Precision (PRAX) Gains Positive Outlook from Oppenheimer | PRAX Stock News - GuruFocus
Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 5.6% – Time to Sell? - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Stock Position Reduced by BNP Paribas Financial Markets - Defense World
(PRAX) Trading Report - news.stocktradersdaily.com
Deutsche Bank AG Buys 5,009 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines to Participate in Upcoming Conferences - GlobeNewswire
Praxis Precision Medicines to Participate in Upcoming Conferences | PRAX Stock News - GuruFocus
What is Chardan Capital’s Forecast for PRAX FY2025 Earnings? - Defense World
Dimensional Fund Advisors LP Decreases Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Northern Trust Corp Raises Stock Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
(PRAX) Investment Report - news.stocktradersdaily.com
Piper Sandler maintains Praxis stock at $270 target, bullish stance By Investing.com - Investing.com India
Praxis Precision Medicines (NASDAQ:PRAX) Research Coverage Started at Chardan Capital - Defense World
Praxis Precision Medicines (PRAX) to Release Earnings on Monday - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Analytical Lens: Exploring Praxis Precision Medicines Inc (PRAX)’s Financial Story Through Ratios - DWinneX
3,008 Shares in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Bought by Envestnet Asset Management Inc. - Defense World
Wedbush Has Positive Outlook for PRAX Q2 Earnings - Defense World
This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - NewsBreak: Local News & Alerts
HC Wainwright Issues Negative Forecast for PRAX Earnings - Defense World
Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside - Benzinga
Chardan Capital Initiates Coverage of Praxis Precision Medicines (PRAX) with Buy Recommendation - Nasdaq
Chardan Capital Initiates Coverage on PRAX with a Buy Rating | PRAX Stock News - GuruFocus
Chardan Initiates Praxis Precision Medicines at Buy With $80 Price Target - marketscreener.com
Chardan Initiates Coverage on Praxis Precision (PRAX) with Buy Rating | PRAX Stock News - GuruFocus
Analysts Issue Forecasts for PRAX Q4 Earnings - Defense World
HC Wainwright Has Bearish Forecast for PRAX FY2029 Earnings - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Given New $28.00 Price Target at Wedbush - Defense World
Analysts Offer Insights on Healthcare Companies: Cerus (CERS), Stryker (SYK) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Praxis Precision Medicines (NASDAQ:PRAX) Receives “Buy” Rating from Needham & Company LLC - Defense World
Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event - GlobeNewswire
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):